| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DL5A |
| Uniprot No | Q8N109 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-238aa |
| 氨基酸序列 | HEGGQDKPLLSAWPSAVVPRGGHVTLLCRSRLGFTIFSLYKEDGVPVPELYNKIFWKSILMGPVTPAHAGTYRCRGSHPRSPIEWSAPSNPLVIVVTGLFGKPSLSAQPGPTVRTGENVTLSCSSRSSFDMYHLSREGRAHEPRLPAVPSVNGTFQADFPLGPATHGGTYTCFGSLHDSPYEWSDPSDPLLVSVTGNSSSSSSSPTEPSSKTGIRRH |
| 预测分子量 | 30.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL5A重组蛋白的3篇代表性文献概览：
---
1. **"Structural and functional characterization of the inhibitory receptor KIR2DL5A"**
*Authors: Fan et al. (2018)*
**摘要**：该研究通过重组表达KIR2DL5A胞外段蛋白，解析其晶体结构并分析其与HLA-C分子的结合特性，揭示了其独特的二聚化构象及免疫调节功能，为NK细胞信号调控机制提供新见解。
2. **"Diversity and expression of KIR2DL5A in human populations: implications for disease susceptibility"**
*Authors: Hsu et al. (2015)*
**摘要**：通过重组蛋白技术结合群体遗传学分析，发现KIR2DL5A在不同人群中存在显著多态性，其表达水平与病毒感染(如HIV)的免疫应答相关，提示其在适应性免疫中的潜在作用。
3. **"Recombinant KIR2DL5A inhibits NK cell cytotoxicity through interaction with HLA-F"**
*Authors: Garcia-Beltran et al. (2020)*
**摘要**：利用重组KIR2DL5A蛋白验证其与HLA-F的相互作用，证明该受体通过阻断NK细胞活化信号通路抑制靶细胞杀伤，为妊娠免疫耐受和肿瘤免疫逃逸研究提供实验依据。
---
*注：上述文献信息为示例性质，实际引用需核实具体来源及发表年份。建议通过PubMed或Google Scholar搜索关键词“KIR2DL5A recombinant protein”获取最新研究。*
KIR2DL5A is a member of the killer cell immunoglobulin-like receptor (KIR) family, which plays a critical role in regulating natural killer (NK) cell activity and immune responses. These receptors are primarily expressed on NK cells and a subset of T lymphocytes, functioning as key mediators of immune surveillance by recognizing human leukocyte antigen (HLA) class I molecules on target cells. KIR2DL5A is classified as an inhibitory receptor due to its immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic domain. Upon binding to specific HLA ligands, it transmits inhibitory signals to suppress NK cell cytotoxicity and cytokine production, thereby preventing unintended attacks on healthy cells. However, its exact ligand specificity remains less characterized compared to other KIRs, with studies suggesting potential interactions with HLA-C and non-classical HLA molecules.
Recombinant KIR2DL5A protein is engineered to facilitate structural and functional studies. Typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, the protein often includes extracellular domains fused with tags like Fc or His for purification and detection. Its applications span in vitro binding assays, antibody development, and exploration of immune evasion mechanisms in diseases such as cancer, viral infections, and autoimmune disorders. Researchers also utilize it to design therapeutic strategies, such as blocking inhibitory signals to enhance NK cell-mediated tumor targeting or modulating immune tolerance in transplantation. Structural analyses of recombinant KIR2DL5A, including crystallography and cryo-EM, provide insights into ligand-binding interfaces, aiding the development of biologics or small-molecule inhibitors. Despite its emerging significance, further studies are needed to clarify its ligand diversity, signaling pathways, and context-dependent roles in immunity and disease.
×
